Clinical Gastroenterology Journal: The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease

Image

Clinical Gastroenterology Journal is a world class open access journal intended to publish the cutting-edge research in the field of Gastroenterology and Hepatology.

Journal of Clinical Gastroenterology endeavours to publish both basic, fundamental and advanced developmental research in all aspects of digestive system, gastrointestinal diseases, liver, bilary tract, pancreas, diseases of related organs Ulcer medicine, Colitis, Diverticulitis and associated disorders and their treatment.

Non-alcoholic fatty liver disease (NAFLD) is excessive fat build-up in the liver with insulin resistance due to causes other than alcohol use.

There are two types:

non-alcoholic fatty liver (NAFL)
non-alcoholic steatohepatitis (NASH), with the latter also including liver inflammation.

Non-alcoholic fatty liver usually does not progress to liver damage or NASH. It may lead to complications such as cirrhosis, liver cancer, liver failure, or cardiovascular disease.

Symptoms:

NAFLD usually causes no signs and symptoms. When it does, they may include:

• Fatigue
• Pain or discomfort in the upper right abdomen

Possible signs and symptoms of NASH and advanced scarring (cirrhosis) include:
• Abdominal swelling (ascites)
• Enlarged blood vessels just beneath the skin's surface
• Enlarged spleen
• Red palms
• Yellowing of the skin and eyes (jaundice)

Causes:

NAFLD and NASH are both linked to the following:
• Overweight or obesity
• Insulin resistance, in which your cells don't take up sugar in response to the hormone insulin
• High blood sugar (hyperglycemia), indicating prediabetes or type 2 diabetes
• High levels of fats, particularly triglycerides, in the blood

Risk factors:
A wide range of diseases and conditions can increase your risk of NAFLD, including:
• High cholesterol
• High levels of triglycerides in the blood
• Metabolic syndrome
• Obesity, particularly when fat is concentrated in the abdomen
• Polycystic ovary syndrome
• Sleep apnea
• Type 2 diabetes
• Underactive thyroid (hypothyroidism)
• Underactive pituitary gland (hypopituitarism)

The main complication of NAFLD and NASH is cirrhosis, which is late stage scarring in the liver. Cirrhosis occurs in response to liver injury, such as the inflammation in NASH. As the liver tries to halt inflammation, it produces areas of scarring (fibrosis). With continued inflammation, fibrosis spreads to take up more and more liver tissue.

In providing both medical and procedural expertise, GEs maintain a close working relationship with hospitalists. We sought to determine the level of satisfaction with gastroenterology consults and procedures overall and with regard to a broad array of specific measures of quality, appropriateness and timeliness of consultative services and endoscopic procedures.

In order to provide a detailed information the journal accepts original manuscripts in the form of Research Articles, Review Articles, Clinical Reviews, Commentaries, Case Reports, Perspectives and Short Communications encompassing all aspects of Clinical Gastroenterology and Hepatology for publication in open access platform.

All the manuscript published by Clinical Gastroenterology Journal are available freely online immediately after publication without any subscription charges or registration.

Submit manuscript directly online at: https://www.scholarscentral.org/submission/clinical-gastreoenterology-journal.html or as an e-mail attachment to the

Editorial Office at: gastroenterology@eclinicalsci.com

How we work:

• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.

• A 21-day window time frame is allotted for peer-review process wherein multiple experts are contacted.

• Author proof is generated within 7 working days after the acceptance decision.

Media Contact
Jessica Watson
Journal Manager
Clinical Gastroenterology Journal
Email: gastroenterology@eclinicalsci.com
WhatsApp: +1-947-333-4405